Abstract 313P
Background
Quantitative analyses of miRNA are potential methods for the detection of carcinoma. Some studies have revealed the importance of microRNAs (miRNAs) function as biomarkers in diagnosing renal cell carcinoma. However, some results are discordant. This study is the first to systematically evaluate the accuracy of circulating miRNA for the diagnosis of renal cell carcinoma found in plasma, serum and urine by conducting meta-analysis.
Methods
We searched PubMed, Embase, Cochrane Library and Google Scholar databases systematically for relevant literatures up to January 10, 2020. The HSROC model was used to calculate the pooled diagnostic parameters and summary receiver operator characteristic (SROC) curve in this meta-analysis, thereby estimating the whole predictive performance. Meta-regression was performed to identify the sources of heterogeneity. All analyses were conducted using RevMan 5.3, MetaDTA, Metadisc Ver 3.0 and Medcalc Ver 19.
Results
This meta-analysis included a total of 18 studies in 12 researches, including 817 renal cell carcinoma patients and 622 healthy controls. The summary estimates for quantitative analysis of miRNA in renal cell carcinoma were as follows: sensitivity, 0.80 (95% confidence interval (CI), 0.75– 0.83); specificity, 0.69 (95% CI, 0.61–0.76); positive likelihood ratio, 2.6 (95% CI, 2.0– 3.2); negative likelihood ratio, 0.28 (95% CI, 0.22–0.34); diagnostic odds ratio, 9.2 (95% CI, 5.7–12.8); and area under the curve, 0.74 (95% CI, 0.70–0.78). Additionally, sub-group and meta-regression analyses revealed that there were no significant differences between ethnicity, year of publication, sample type and miRNA profiling. There was no statistical significance for the evaluation of publication bias.
Conclusions
Current evidence suggests that quantitative analysis of miRNA has acceptable sensitivity but unsatisfactory specificity for the diagnosis of renal cell carcinoma. Further large-scale prospective studies are required to validate the potential applicability of using miRNA alone or in combination with diagnostic test for renal cell carcinoma and explore potential factors that may influence the accuracy of renal cell carcinoma diagnosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jestoni V. Aranilla MD.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session